NasdaqGS - Nasdaq Real Time Price • USD
Compare
At close: 3 September at 16:00 GMT-4
After hours: 3 September at 18:33 GMT-4
Line
Candle
Baseline
Mountain
Bar
Loading Chart for AMGN
9/21 12:03 PM
DELL
Date | |
Close | |
Open | |
High | |
Low | |
Volume |
- Previous close
333.83 - Open
331.59 - Bid 330.33 x 100
- Ask 330.81 x 100
- Day's range
329.10 - 333.00 - 52-week range
248.38 - 346.85 - Volume
2,120,082 - Avg. Volume
2,074,891 - Market cap (intra-day)
177.593B - Beta (5Y monthly) 0.61
- PE ratio (TTM)
57.08 - EPS (TTM)
5.79 - Earnings date 29 Oct 2024 - 4 Nov 2024
- Forward dividend & yield 9.00 (2.72%)
- Ex-dividend date 16 Aug 2024
- 1y target est
328.50
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
26,700
Full-time employees
31 December
Fiscal year ends
Healthcare
Sector
Drug Manufacturers - General
Industry
More about Amgen Inc.
Recent news: AMGN
View moreAll SEC filings
Corporate changes and voting matters
Periodic financial reports
Proxy statements
Tender offer/acquisition reports
Offering registrations
Performance overview: AMGN
Trailing total returns as of 03/09/2024, which may include dividends or other distributions. Benchmark is
YTD return
AMGN
17.28%
S&P 500
15.91%
1-year return
AMGN
32.62%
S&P 500
22.44%
3-year return
AMGN
60.90%
S&P 500
21.86%
5-year return
AMGN
84.31%
S&P 500
88.93%
Compare to: AMGN
Compare
Select to analyse similar companies using key performance metrics; select up to four stocks.
330.51
-0.99%
Mkt cap 177.593B
Industry Drug Manufacturers—General
197.69
+0.70%
Mkt cap 349.188B
Industry Drug Manufacturers—General
116.58
-1.58%
Mkt cap 295.508B
Industry Drug Manufacturers—General
79.70
+0.89%
Mkt cap 99.226B
Industry Drug Manufacturers—General
50.52
+1.14%
Mkt cap 102.424B
Industry Drug Manufacturers—General
Mkt cap 402.394B
Industry Drug Manufacturers—General
204.84
+0.04%
Mkt cap 29.837B
Industry Drug Manufacturers—General
85.72
-2.17%
Mkt cap 265.778B
Industry Drug Manufacturers—General
956.53
-0.36%
Mkt cap 861.284B
Industry Drug Manufacturers—General
118.50
-1.98%
Mkt cap 244.398B
Industry Drug Manufacturers—General
28.30
-2.45%
Mkt cap 160.368B
Industry Drug Manufacturers—General
Statistics: AMGN
View more
Valuation measures
As of 03/09/2024
Market cap
177.69B
Enterprise value
231.03B
Trailing P/E
57.02
Forward P/E
16.10
PEG ratio (5-yr expected)
2.28
Price/sales (ttm)
5.77
Price/book (mrq)
29.99
Enterprise value/revenue
7.47
Enterprise value/EBITDA
19.56
Financial highlights
Profitability and income statement
Profit margin
10.12%
Return on assets (ttm)
4.48%
Return on equity (ttm)
49.27%
Revenue (ttm)
30.93B
Net income avi to common (ttm)
3.13B
Diluted EPS (ttm)
5.79
Balance sheet and cash flow
Total cash (mrq)
9.3B
Total debt/equity (mrq)
1,057.30%
Levered free cash flow (ttm)
3.01B
Research analysis: AMGN
View morePeople also watch
BIIB Biogen Inc.
204.84
+0.04%
GILD Gilead Sciences, Inc.
79.70
+0.89%
BMY Bristol-Myers Squibb Company
50.52
+1.14%
MRK Merck & Co., Inc.
116.58
-1.58%
LLY Eli Lilly and Company
956.53
-0.36%
ABT Abbott Laboratories
114.66
+1.23%
UNH UnitedHealth Group Incorporated
598.68
+1.44%
MDT Medtronic plc
88.96
+0.43%
JNJ Johnson & Johnson
167.16
+0.78%
ABBV AbbVie Inc.
197.69
+0.70%
REGN Regeneron Pharmaceuticals, Inc.
1,168.81
-1.34%
VRTX Vertex Pharmaceuticals Incorporated
475.70
-4.07%
PFE Pfizer Inc.
28.30
-2.45%
NVS Novartis AG
118.50
-1.98%
TXN Texas Instruments Incorporated
201.83
-5.84%
AMAT Applied Materials, Inc.
183.37
-7.04%